Oncodesign Precision Medicine Sets IPO Through Direct Listing on Euronext Access + Paris

Oncodesign Precision Medicine, a biopharmaceutical company specializing in medicine for the treatment of resistant and metastatic cancers, announced that it will launch an IPO on Euronext Access + Paris through a direct quotation Oct. 5.

The company intends to offer nearly 6.9 million shares at €0.817 each (approximately $5.9 million). Read more.

Total
0
Shares
Related Posts
Blank Check company
Read More

Cashing Blank Checks – Why the Bold Favor SPACs: Analysis

Confident financial projections are common in SPAC deals and have been a decisive factor in attracting firms regarded as more risky, often loss-making and years away from even having any sales, over IPOs as a route to going public, Reuters reports, citing industry insiders and the news organization's review of data compiled by Jay Ritter, a professor at the University of Florida.